Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement

INTRODUCTION: Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) shows poor response rates in non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) patients with multiple extranodal involvement. This study aims to evaluate anti-tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Hongzhi, Jia, Sixun, Zhang, Ying, Li, Jiaqi, Yang, Qin, Zeng, Liangyu, Zong, Xiangping, Lu, Yutong, Lu, Shuangzhu, Zhou, Jin, Li, Caixia, Wu, Depei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476090/
https://www.ncbi.nlm.nih.gov/pubmed/37671152
http://dx.doi.org/10.3389/fimmu.2023.1219167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476090/
https://www.ncbi.nlm.nih.gov/pubmed/37671152
http://dx.doi.org/10.3389/fimmu.2023.1219167

Ejemplares similares